Gilead Puts Biotech ETFs in Focus - ETF News And Commentary
11 Março 2013 - 7:51AM
Zacks
California-based Gilead Sciences (GILD) was in focus last week
as it saw some encouraging clinical trial data on its HIV pill—TAF.
This report pushed up GILD by about 4.5% last week and helped many
biotech ETFs surge in the time frame as well.
This has obviously been particularly true for those funds that
have major holdings in GILD. In fact, these ETFs clearly outpaced
the broader market funds like SPDR S&P 500 ETF (SPY) and Dow
Jones Industrial Average ETF (DIA) by a wide margin over the
trailing one-week period.
The SPDR S&P Biotech ETF (XBI) led the
sector with 5.39% gain followed by iShares NASDAQ
Biotechnology Fund (IBB), which added 4.07% in the past
five day period. Being the most popular funds, these products saw a
good weekly volume of 1.8 million and 2.5 million shares,
respectively (read: Biotech ETFs: A Fiscal Cliff Safe Haven?).
XBI tracks the S&P Biotechnology Select Industry Index,
holding 51 stocks while IBB tracks the NASDAQ Biotechnology index,
holding 120 securities. The former focuses on small cap companies
while the latter centers on large caps. State Street product
charges low fee of just 35 bps a year while the iShares product
charges 48 bps a year.
The top three holdings of XBI consist of Isis Pharmaceuticals
(ISIS), Pharmacyclics (PCYC) and Incyte (INCY) all of which account
for less than 4.1% of assets. Meanwhile, top stocks in IBB include
Regeneron Pharma (REGN), GILD and Amgen (AMGN), all of which make
up at least 8% of assets.
Another strong performer on the week was the Market
Vectors Biotech ETF (BBH), which gained 4.01% in the same
timeframe by tracking the Market Vectors US Listed Biotech 25
Index. It has amassed over $197 million in AUM and 194,000 shares
in weekly volume.
The fund holds 26 securities in its basket and charges a low
annual fee of 35 bps. This is also the large cap centric fund and
is somewhat concentrated from an individual security perspective
with AMGN and GILD combining to take up about 25% of assets (see
more ETFs in the Zacks ETF Center).
First Trust NYSE Arca Biotechnology Index Fund
(FBT) added 3.72% in the same time frame. The fund tracks
the Amex biotechnology Index, utilizing an equal weight technique
for its approach. The fund is expensive at 60 basis points a year
while weekly volume and total AUM are respectable at 352,000 shares
a day and $275 million, respectively.
With 20 stocks in its basket, the fund has a nice mix of all cap
securities with top three holdings include INCY, Biogen Idec (BIIB)
and United Therapeutics (UTHR), each of which make up, on average,
6% of the fund (read: Top Ranked Biotech ETF: FBT).
PowerShares Dynamic Biotech & Genome (PBE),
the least popular in the space, gained 2.95% in the past five
trading session. The fund follows the Dynamic Biotechnology &
Genome Intellidex Index, holding 30 stocks in the basket. Though it
failed to attract investors with just 51,000 shares exchange hands,
it has amassed over $140 million in AUM.
The ETF is tilted toward small cap securities. The top three
holdings - REGN, AMGN and GILD – each make up for 5% of the assets
on average. The fund costs 60 bps per year and could be a more
volatile play on the biotech world.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30
Days. Click to get this free report >>
MKT VEC-BIOTECH (BBH): ETF Research Reports
FT-AMEX BIOTEC (FBT): ETF Research Reports
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ISHARES NDQ BIO (IBB): ETF Research Reports
PWRSH-DYN BIO (PBE): ETF Research Reports
SPDR-SP BIOTECH (XBI): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days. Click
to get this free report
SPDR S&P Biotech (AMEX:XBI)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
SPDR S&P Biotech (AMEX:XBI)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024